|
SERPINE1
|
Plasminogen Activator Inhibitor-1 Deficiency
|
0.700 |
CausalMutation |
CLINVAR |
Life-threatening hemorrhage and prolonged wound healing are remarkable phenotypes manifested by complete plasminogen activator inhibitor-1 deficiency in humans.
|
21486382 |
2011 |
|
SERPINE1
|
Plasminogen Activator Inhibitor-1 Deficiency
|
0.700 |
GermlineCausalMutation |
ORPHANET |
Human plasminogen activator inhibitor-1 (PAI-1) deficiency: characterization of a large kindred with a null mutation in the PAI-1 gene.
|
9207454 |
1997 |
|
SERPINE1
|
Plasminogen Activator Inhibitor-1 Deficiency
|
0.700 |
CausalMutation |
CLINVAR |
Brief report: complete deficiency of plasminogen-activator inhibitor type 1 due to a frame-shift mutation.
|
1435917 |
1992 |
|
SERPINE1
|
Plasminogen Activator Inhibitor-1 Deficiency
|
0.700 |
Biomarker |
CTD_human |
|
|
|
|
SERPINE1
|
Plasminogen Activator Inhibitor-1 Deficiency
|
0.700 |
Biomarker |
GENOMICS_ENGLAND |
|
|
|
|
SERPINE1
|
Diabetic Nephropathy
|
0.600 |
Biomarker |
BEFREE |
Collectively, our findings provide support that PAI-1 contributes to the development of inflammation in perirenal fat and correlates with the development of diabetic nephropathy in HFD-induced obesity.
|
30532990 |
2019 |
|
SERPINE1
|
Hypertensive disease
|
0.600 |
Biomarker |
BEFREE |
Addition of waist circumference to the models either decreased or nullified the contribution of PAI-1act to BP and hypertension development.
|
31356402 |
2019 |
|
SERPINE1
|
Hypertensive disease
|
0.600 |
GeneticVariation |
BEFREE |
Hypertension (odds ratio [OR] = 1.953, p = 0.020), tHcy (OR = 1.059, p = 0.029), thyroid-stimulating hormone (OR = 0.876, p = 0.039), and the PAI-1 genotype dominant allele model (OR = 1.748, p = 0.047) were associated with IS by multivariate analysis.
|
30160528 |
2018 |
|
SERPINE1
|
Hypertensive disease
|
0.600 |
Biomarker |
BEFREE |
These results demonstrates that hypertension and insulin resistance induced by COC is associated with increased cardiac RAS and PAI-1 gene expression, which is likely to be through corticosterone-dependent but not aldosterone-dependent mechanism.
|
26934364 |
2017 |
|
SERPINE1
|
Hypertensive disease
|
0.600 |
GeneticVariation |
BEFREE |
The most significant result among all univariate and multivariate tests performed in this study was the heterogeneity of correlation between PAI-1 and mean arterial pressure at rs10738554, near SLC24A2, a gene previously associated with high blood pressure in African Americans.
|
28408189 |
2017 |
|
SERPINE1
|
Hypertensive disease
|
0.600 |
Biomarker |
BEFREE |
We observed significantly lower concentration of PAI-1:Ag in DF patients treated for hypertension as compared to patients without hypertension.
|
28193577 |
2017 |
|
SERPINE1
|
Hypertensive disease
|
0.600 |
Biomarker |
BEFREE |
Although Angiotensin II-induced hypertension was blunted in PAI-1<sup>-/-</sup> mice, cardiac hypertrophy was accelerated.
|
28588076 |
2017 |
|
SERPINE1
|
Hypertensive disease
|
0.600 |
Biomarker |
BEFREE |
Analysis using categorical PAI-1 (in tertiles) showed that participants in the highest tertile (≥58 ng/ml) had 63% increased risk for hypertension [OR = 1.63 (1.12-2.37)] compared with those in the lowest tertile (<33 ng/ml).
|
28379891 |
2017 |
|
SERPINE1
|
Hypertensive disease
|
0.600 |
AlteredExpression |
BEFREE |
A model with components of MetS explained only 12% of variability on PAI-1 levels (<i>R</i><sup>2</sup> = 0.12; <i>p</i> = 0.001), with <i>β</i> = 0.18 (<i>p</i> = 0.03) for hypertension, <i>β</i> = -0.16 (<i>p</i> = 0.05) for NL HDL-c, and <i>β</i> = 0.15 (<i>p</i> = 0.05) for NL triglycerides.<i>Conclusion</i>.
|
28271069 |
2017 |
|
SERPINE1
|
Diabetic Nephropathy
|
0.600 |
GeneticVariation |
BEFREE |
Association of plasminogen activator inhibitor-1 gene polymorphism and type 2 diabetic nephropathy.
|
26616527 |
2016 |
|
SERPINE1
|
Diabetic Nephropathy
|
0.600 |
Therapeutic |
RGD |
Panax notoginseng saponins protect kidney from diabetes by up-regulating silent information regulator 1 and activating antioxidant proteins in rats.
|
26712211 |
2016 |
|
SERPINE1
|
Hypertensive disease
|
0.600 |
AlteredExpression |
BEFREE |
The presence of type 2 diabetes associated with 3.2-fold increased PAI-1 expression (adjusted p=0.033), while the presence of hypertension associated with about 50% reduction of IL-8 and TIMP-1.
|
25496999 |
2015 |
|
SERPINE1
|
Diabetic Nephropathy
|
0.600 |
GeneticVariation |
BEFREE |
A meta-analysis was conducted to investigate the association between 4 G/5 G variants in the PAI-1 gene and DN susceptibility.
|
24345290 |
2014 |
|
SERPINE1
|
Diabetic Nephropathy
|
0.600 |
Biomarker |
BEFREE |
Therefore, PAI-1R provides an additional therapeutic effect in slowing the progression of diabetic nephropathy via the protection of podocytes.
|
24443353 |
2014 |
|
SERPINE1
|
Hypertensive disease
|
0.600 |
GeneticVariation |
BEFREE |
Stroke prevalence and odds ratio (OR) were assessed for the following parameters: G20210A prothrombin, Arg506Glu factor V Leiden, C677T MTHFR, and 4G/5G PAI-1 polymorphisms; total number of study polymorphisms in a particular subject (genetic sum); and classic vascular risk factors of hypertension, obesity, diabetes mellitus, cigarette smoking, hypercholesterolemia, hypertriglyceridemia, and elevated levels of low-density lipoprotein (LDL) cholesterol and very low-density lipoprotein cholesterol.
|
24189452 |
2014 |
|
SERPINE1
|
Hypertensive disease
|
0.600 |
AlteredExpression |
BEFREE |
Hypertension is associated with increased expression of FABP3, FAS, FN1, IL1R2, LPL, SERPINE1, TGFB1, and VCAM1 and decreased expression of SELPLG and SERPINEB2.
|
23337395 |
2014 |
|
SERPINE1
|
Diabetic Nephropathy
|
0.600 |
GeneticVariation |
BEFREE |
Using allelic comparison (4G vs. 5G), the PAI-1 -675 4G/5G polymorphism was observed to have no significant association with diabetes (REM OR 1.07, 95% CI 0.96, 1.20), DN (REM OR 1.10, 95% CI 0.98, 1.25), DR (REM OR 1.09, 95% CI 0.97, 1.22) or diabetic CAD risk (REM OR 1.07, 95% CI 0.81, 1.42), and similar results were obtained in the dominant, recessive and co-dominant models.
|
24223897 |
2013 |
|
SERPINE1
|
Hypertensive disease
|
0.600 |
GeneticVariation |
BEFREE |
When stratified according to PAI-1 4G/5G polymorphism, there was no significant difference in all metabolic parameters among PAI-1 genotype groups in patients with HTN as well as subjects with normal blood pressure.
|
22613596 |
2012 |
|
SERPINE1
|
Hypertensive disease
|
0.600 |
Biomarker |
CTD_human |
Vascular and thrombogenic effects of pulmonary exposure to Libby amphibole.
|
22352330 |
2012 |
|
SERPINE1
|
Hypertensive disease
|
0.600 |
GeneticVariation |
BEFREE |
The functional plasminogen activator inhibitor-1 (PAI-1) 4G/5G polymorphism has previously been associated with hypertension.
|
21490692 |
2011 |